Skip to content

Investigation of Dynamic Hyperinflation and Its Relationship With Functional Exercise Capacity in Children With Bronchiectasis

Investigation of Dynamic Hyperinflation and Its Relationship With Functional Exercise Capacity in Children With Bronchiectasis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04885790
Enrollment
40
Registered
2021-05-13
Start date
2021-06-01
Completion date
2021-08-10
Last updated
2021-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Keywords

bronchiectasis, children, dynamic hyperinflation, exercise capacity, pulmonary function

Brief summary

Prevalence of dynamic hyperinflation and its relationship with functional exercise capacity will be evaluated in children with bronchiectasis.

Detailed description

Exercise or hyperpnea-induced air trapping is referred to as dynamic hyperinflation. In the presence of high resistance to expiratory flows and short expiratory times, the respiratory system is unable to return to its resting volume at the end of exhalation. The positive pressure within regions of hyperinflated lung raises the mean intrathoracic pressure and causes the inspiratory muscles to operate at a higher than resting lung volume. Thus, dynamic hyperinflation places the respiratory muscles at a considerable mechanical disadvantage and further impairs respiratory function. Dynamic hyperinflation is considered to be a key determinant of exercise capacity in patients with obstructive lung diseases. Although bronchiectasis is one of the obstructive lung diseases, the presence of dynamic hyperinflation in these patients has not been adequately investigated. Management guidelines of bronchiectasis state that imaging methods or pulmonary function tests alone is not sufficient to determine the disease burden and prognosis in these patients, so they recommend including detailed evaluation of exercise tolerance in the management of bronchiectasis. Aim of this study is to investigate the prevalence of dynamic hyperinflation and its relationship with functional exercise capacity in children with bronchiectasis.

Interventions

OTHERRespiratory assessment using Spiropalm 6MWT portable spirometry

Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry.

Functional exercise capacity of patients will be evaluated using six-minute walk test.

OTHEREvaluation of peripheral muscle strength

Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.

OTHEREvaluation of chronic cough

The Leicester Cough Questionnaire will be used for evaluating cough.

Sponsors

Ege University
CollaboratorOTHER
Izmir Bakircay University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
8 Years to 18 Years

Inclusion criteria

* Diagnosis of bronchiectasis

Exclusion criteria

* Hospitalization history during past month * Diagnosis of any other chronic childhood diseases such as cerebral palsy or neuromuscular diseases which may impede exercise tolerance

Design outcomes

Primary

MeasureTime frameDescription
Dynamic hyperinflationAt baselineDynamic hyperinflation will be defined as a decrease of \>100 mL in inspiratory capacity at the end of six-minute walk test determined by Spiropalm 6MWT device.

Secondary

MeasureTime frameDescription
Six-minute walk distanceAt baselineDistance walked in six minutes will be recorded. Test will be conducted according to the guideline of American Thoracic Society.
Minute ventilationAt baselineMaximum minute ventilation during six-minute walk test will be measured via Spiropalm 6MWT device.
Breathing reserveAt baselineBreathing reserve (BR) will be calculated as the difference between the maximal voluntary ventilation (MVV) and the maximum minute ventilation (VE) as a fraction of the MVV using Spiropalm 6MWT during six-minute walk test.
Forced Vital Capacity (FVC)At baselineFVC will be measured before six-minute walk test according to the guideline of European Respiratory Society.
M. Quadriceps strengthAt baselineM. Quadriceps strength will be measured using hand-held dynamometer
Peak Expiratory Flow (PEF)At baselinePEF will be measured before six-minute walk test according to the guideline of European Respiratory Society.
Handgrip strengthAt baselineHandgrip strength will be measured using handgrip dynamometer.
Leicester Cough QuestionnaireAt baselineChronic cough will be evaluated using Leicester Cough Questionnaire. Questionnaire consists of 19 items covering physical, psychological and social domains with a 7 point likert response scale (range from 1 to 7). Higher score indicates better quality of life.
Forced Expiratory Volume in 1 second (FEV1)At baselineFEV1 will be measured before six-minute walk test according to the guideline of European Respiratory Society.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026